Evommune, Inc. (EVMN)
12.17
-0.31
(-2.48%)
USD |
NYSE |
Sep 03, 12:49
Evommune Research and Development Expense (TTM) : 83.77M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.77M |
| March 31, 2026 | 77.00M |
| December 31, 2025 | 74.04M |
| Date | Value |
|---|---|
| September 30, 2025 | 66.93M |
| June 30, 2025 | 72.47M |
| March 31, 2025 | 60.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| MapLight Therapeutics, Inc. | 198.70M |
| Mineralys Therapeutics, Inc. | 301.59M |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| Oncolytics Biotech, Inc. | 13.11M |
| Sangamo Therapeutics, Inc. | 113.79M |